A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Certolizumab pegol (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms CIMPACT
  • Sponsors UCB
  • Most Recent Events

    • 14 Sep 2017 According to an UCB media release, 48-week data from CIMPASI-1, CIMPASI-2 and CIMPACT trials were presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress.
    • 14 Sep 2017 48-week safety and efficacy results from CIMPASI-1, CIMPASI-2 and CIMPACT trials published in an UCB media release.
    • 11 Sep 2017 Planned End Date changed from 1 Jan 2019 to 3 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top